Carl Zeiss Meditec (ETR:AFX) PT Set at €162.00 by UBS Group

Carl Zeiss Meditec (ETR:AFX – Get Rating) has been assigned a €162.00 ($172.34) price objective by analysts at UBS Group in a note issued to investors on Thursday, Borsen Zeitung reports. UBS Group’s price target points to a potential upside of 18.99% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Berenberg Bank set a €138.00 ($146.81) target price on shares of Carl Zeiss Meditec in a research report on Monday, February 13th. Hauck Aufhäuser Investment Banking set a €195.00 ($207.45) price target on Carl Zeiss Meditec in a report on Monday, February 6th. Finally, Deutsche Bank Aktiengesellschaft set a €175.00 ($186.17) price target on shares of Carl Zeiss Meditec in a research report on Friday, February 24th.

Carl Zeiss Meditec Stock Down 0.3 %

Shares of ETR AFX opened at €136.15 ($144.84) on Thursday. Carl Zeiss Meditec has a 52 week low of €101.75 ($108.24) and a 52 week high of €154.05 ($163.88). The stock’s fifty day moving average is €131.14 and its 200 day moving average is €124.59. The company has a debt-to-equity ratio of 6.30, a quick ratio of 2.47 and a current ratio of 3.32. The stock has a market capitalization of $12.18 billion, a P/E ratio of 49.85, a PEG ratio of 3.75 and a beta of 0.80.

About Carl Zeiss Meditec

(Get Rating)

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers offers products and solutions for the diagnosis and treatment of chronic eye diseases; and systems and consumables for refractive surgery.